The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
Open accessAbstract
Background—: The aim of this study was to compare the management and prognosis of major bleeding in patients treated with dabigatran or warfarin. Methods and Results—: Two independent investigators reviewed bleeding reports from 1034 individuals with 1121 major bleeds enrolled in 5 phase III trials comparing dabigatran with warfarin in 27 419 patients treated for 6 to 36 months. Patients with major bleeds on dabigatran (n=627 of 16 755) were older, had lower creatinine clearance, and more frequently used aspirin or non-steroid anti-inflammatory agents than those on warfarin (n=407 of 10 002). The 30-day mortality after the first major bleed tended to be lower in the dabigatran group (9.1%) than in the warfarin group (13.0%; pooled odds ratio, 0.68; 95% confidence interval, 0.46–1.01; P =0.057). After adjustment for sex, age, weight, renal function, and concomitant antithrombotic therapy, the pooled odds ratio for 30-day mortality with dabigatran versus warfarin was 0.66 (95% confidence interval, 0.44–1.00; P =0.051). Major bleeds in dabigatran patients were more frequently treated with blood transfusions (423/696, 61%) than bleeds in warfarin patients (175/425, 42%; P <0.001) but less frequently with plasma (dabigatran, 19.8%; warfarin, 30.2%; P <0.001). Patients who experienced a bleed had shorter stays in the intensive care unit if they had previously received dabigatran (mean 1.6 nights) compared with those who had received warfarin (mean 2.7 nights; P =0.01). Conclusions—: Patients who experienced major bleeding on dabigatran required more red cell transfusions but received less plasma, required a shorter stay in intensive care, and had a trend to lower mortality compared with those who had major bleeding on warfarin. Clinical Trial Registration—: URL: http://www.ClinicalTrials.gov . Unique identifiers: NCT00262600, NCT00291330, NCT00680186, NCT00329238 and NCT00558259.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Developed with the special contribution of the European Heart Rhythm Association (EHRA), Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), Authors/Task Force Members, Camm, A. J., Kirchhof, P., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Van Gelder, I. C., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,864
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Self-citationEffect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Stangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0758 · Cited by 1,382
Evidence-Based Management of Anticoagulant Therapy
Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., Veenstra, D. L., Crowther, M., & Guyatt, G. H. (2012) · Chest · doi:10.1378/chest.11-2295 · Cited by 1,269
Self-citationHematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage
Davis, S. M., Broderick, J., Hennerici, M., Brun, N. C., Diringer, M. N., Mayer, S. A., Begtrup, K., & Steiner, T. (2006) · Neurology · doi:10.1212/01.wnl.0000208408.98482.99 · Cited by 1,168
Eikelboom, J. W., Wallentin, L., Connolly, S. J., Ezekowitz, M., Healey, J. S., Oldgren, J., Yang, S., Alings, M., Kaatz, S., Hohnloser, S. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004747 · Cited by 1,081 · cited 1×
“There was no interaction between renal function as assessed by the Cockcroft-Gault formula and treatment, which is a surprising finding because renal function is a determinant of dabigatran exposure.(23) Other analyses have not consistently shown that renal dysfunction is a risk factor for bleeding in patients treated…”
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1113697 · Cited by 983
Self-citationStangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02899.x · Cited by 887
Hansen, M. L., Sørensen, R., Clausen, M. T., Fog-Petersen, M. L., Raunsø, J., Gadsbøll, N., Gislason, G. H., Folke, F., Andersen, S. S., Schramm, T. K., et al. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.271 · Cited by 855 · cited 1×
“Concomitant antiplatelet therapy has been shown to increase the risk of bleeding in patients on warfarin and dabigatran.(26,27) The higher prevalence of these risk factors in patients treated with dabigatran compared with warfarin who experienced major bleeding suggests that dabigatran is associated with a higher thre…”
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
Schulman, S., Beyth, R. J., Kearon, C., & Levine, M. N. (2008) · Chest · doi:10.1378/chest.08-0674 · Cited by 740
Self-citationStangier, J., Rathgen, K., Stähle, H., & Mazur, D. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318170-000000000-00000 · Cited by 722
Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage
Flibotte, J. J., Hagan, N., O’Donnell, J., Greenberg, S. M., & Rosand, J. (2004) · Neurology · doi:10.1212/01.wnl.0000138428.40673.83 · Cited by 632
A specific antidote for dabigatran: functional and structural characterization
Schiele, F., van Ryn, J., Canada, K., Newsome, C., Sepulveda, E., Park, J., Nar, H., & Litzenburger, T. (2013) · Blood · doi:10.1182/blood-2012-11-468207 · Cited by 563
Dans, A. L., Connolly, S. J., Wallentin, L., Yang, S., Nakamya, J., Brueckmann, M., Ezekowitz, M., Oldgren, J., Eikelboom, J. W., Reilly, P. A., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.115386 · Cited by 484
Self-citationMeta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency
Lim, W., Dentali, F., Eikelboom, J. W., & Crowther, M. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-9-200605020-00011 · Cited by 443
Self-citationHart, R. G., Diener, H.-C., Yang, S., Connolly, S. J., Wallentin, L., Reilly, P. A., Ezekowitz, M. D., & Yusuf, S. (2012) · Stroke · doi:10.1161/strokeaha.112.650614 · Cited by 406
Self-citationHuttner, H. B., Schellinger, P. D., Hartmann, M., Köhrmann, M., Juettler, E., Wikner, J., Mueller, S., Meyding-Lamade, U., Strobl, R., Mansmann, U., et al. (2006) · Stroke · doi:10.1161/01.str.0000221786.81354.d6 · Cited by 335
Zhou, W., Schwarting, S., Illanes, S., Liesz, A., Middelhoff, M., Zorn, M., Bendszus, M., Heiland, S., van Ryn, J., & Veltkamp, R. (2011) · Stroke · doi:10.1161/strokeaha.111.624650 · Cited by 324
Bleeding Risk with Dabigatran in the Frail Elderly
Harper, P., Young, L., & Merriman, E. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1112874 · Cited by 285
Holland, L. L., & Brooks, J. P. (2006) · American Journal of Clinical Pathology · doi:10.1309/nqxhug7hnd78lffk · Cited by 253
Holland, L. L., & Brooks, J. P. (2006) · American Journal of Clinical Pathology · doi:10.1309/nqxh-ug7h-nd78-lffk · Cited by 239
Warkentin, T. E., Margetts, P., Connolly, S. J., Lamy, A., Ricci, C., & Eikelboom, J. W. (2012) · Blood · doi:10.1182/blood-2011-11-393587 · Cited by 207
Self-citationFormella, S., Wiegert, E., Moschetti, V., Slowinski, T., Neumayer, H.-H., Liesenfeld, K.-H., Lehr, T., Härtter, S., Friedman, J., Khadzhynov, D., et al. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-08-0573 · Cited by 207
Acutely Injured Patients on Dabigatran
Cotton, B. A., McCarthy, J. J., & Holcomb, J. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1111095 · Cited by 160
Friedman, R. J., Dahl, O. E., Rosencher, N., Caprini, J. A., Kurth, A. A., Francis, C. W., Clemens, A., Hantel, S., Schnee, J. M., & Eriksson, B. I. (2010) · Thrombosis Research · doi:10.1016/j.thromres.2010.03.021 · Cited by 141
Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin
Minematsu, K., Naritomi, H., Sakata, T., Yamaguchi, T., & Yasaka, M. (2003) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613443 · Cited by 134
Schulman, S., Kakkar, A. K., Schellong, S., Goldhaber, S. Z., Henry, E., Mismetti, P., Christiansen, A. V., Schnee, J. M., & Kearon, C. (2011) · Blood · doi:10.1182/blood.v118.21.205.205 · Cited by 95
Self-citationWolf, M., Soufir, L., Galbois, A., Dumenil, A.-S., Offenstadt, G., Samama, M., & Louët, A. L. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-03-0149 · Cited by 70
Helldén, A., Odar‐Cederlöf, I., Nilsson, G., et al. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-002686 · Cited by 43
Dabigatran: Uncharted Waters and Potential Harms
Radecki, R. P. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-1-201207030-00467 · Cited by 30
Cited by
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Holmes, D. R., Kar, S., Price, M. J., Whisenant, B., Sievert, H., Doshi, S. K., Huber, K., & Reddy, V. Y. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.029 · Cited by 1,845
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015) · Europace · doi:10.1093/europace/euv309 · Cited by 1,113
Metadata
- Authors
- Majeed, A., Hwang, H.-G., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Wallentin, L., Brueckmann, M., Fraessdorf, M., Yusuf, S., & Schulman, S.
- Venue
- Circulation
- Published
- 2013-11-19
- Volume
- 128
- Issue
- 21
- Pages
- 2325-2332
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2101863341
- Cited by
- 277
- References
- 35
- FWCI
- 37.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.